Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial

被引:0
作者
Nancy Devlin
Michael Herdman
Marco Pavesi
De Phung
Shevani Naidoo
Tomasz M. Beer
Bertrand Tombal
Yohann Loriot
Cristina Ivanescu
Teresa Parli
Mark Balk
Stefan Holmstrom
机构
[1] Office of Health Economics,
[2] European Association for the Study of the Liver–Chronic Liver Failure (EASL-CLIF) Consortium,undefined
[3] Astellas Pharma Global Development,undefined
[4] Astellas Medical Affairs,undefined
[5] Global Health Economic Outcomes Research (HEOR),undefined
[6] OHSU Knight Cancer Institute,undefined
[7] Oregon Health & Science University,undefined
[8] Institut de Recherche Clinique (IREC),undefined
[9] Cliniques Universitaires Saint Luc,undefined
[10] Institut Gustave Roussy,undefined
[11] University of Paris Sud,undefined
[12] Quintiles,undefined
[13] Medivation,undefined
[14] Inc.,undefined
[15] Astellas Medical Affairs,undefined
[16] Global HEOR,undefined
来源
Health and Quality of Life Outcomes | / 15卷
关键词
Metastatic castration-resistant prostate cancer; Enzalutamide; Quality of life; Eq-5D;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 153 条
[1]  
Sandblom G(2004)A population-based study of pain and quality of life during the year before death in men with prostate cancer Br J Cancer 90 1163-1168
[2]  
Carlsson P(2007)Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer Qual Life Res 16 571-575
[3]  
Sennfält K(2012)Symptoms and health-related quality of life in castration-resistant prostate cancer: the patient's perspective J Mens Health 9 9-16
[4]  
Varenhorst E(2013)Perspectives on treatment of metastatic castration-resistant prostate cancer Oncologist 18 558-567
[5]  
Sullivan PW(2014)Castration-resistant prostate cancer: latest evidence and therapeutic implications Ther Adv Med Oncol 6 167-179
[6]  
Mulani PM(2008)Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group J Clin Oncol 26 1148-1159
[7]  
Fishman M(1997)Measuring quality of life in men with prostate cancer using the Functional assessment of cancer therapy-prostate instrument Urology 50 920-928
[8]  
Sleep D(1993)The European Organization for Research and Treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 365-366
[9]  
Payne H(1990)EuroQol--a new facility for the measurement of health-related quality of life Health Policy 16 199-208
[10]  
Pearcy R(2001)EQ-5D: a measure of health status from the EuroQol group Ann Med 33 337-343